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The oral region has a role in various essential and com-
plex functions to breath, masticate, swallow and vocal-
ize, which are important for sustaining life. The oral re-
gion extends from the lips to the palatoglossal fold, clas-
sified into the lips, buccal mucosa, gingiva, floor of the 
mouth, tongue and palate. Although it contains various 
anatomically distinct tissues, squamous cell carcinoma 
(SCC) accounts for more than 90% of all malignant tu-
mors originating in the oral region.1 Unlike SCC of the 
skin and other organs, SCC of the oral region is likely to 
metastasize to the cervical lymph nodes at an early pe-
riod, so cervical lymph node metastasis is considered to 
be a prognostic factor for patients with oral cancer.2, 3
 Regarding the relationship between oral SCC and 
cervical lymph node involvement, an association with 
histological grade and tumor size was suggested,4 while 
association with cervical metastasis of histological grade 
but no primary tumor location or size5 was suggested. 
Lymphatic vessels in the tongue have many connections 
and are linked across the midline. This anatomy of the 
lymphatics suggests that tumors in the oral region can 
easily metastasize to the opposite side from the primary 
tumor or can cause bilateral metastases.1 
 In order to establish lymph node metastasis, it is also 
essential for tumor lymphangiogenesis to be induced. 
Previously, SCC of the oral cavity, larynx/pharynx 
and esophagus, and squamous cancer of the lungs and 
gastrointestinal tract were investigated regarding the 
relationship between tumors and lymphangiogenesis by 
means of assessment of lymphatic vessel density (LVD) 
and expression of vascular endothelial growth factors 
(VEGFs).6–11 However, there is no detailed study of 
the associations of site-specific LVD in oral SCC with 
VEGF expression or clinicopathological findings. In the 
present study, we performed histopathological assess-
ment of LVD in over 100 patients with oral SCC, and 
examined the association between LVD and clinico-
pathological findings. Our results showed that, contrary 
to the previous reports, LVD in peritumoral tissue “hot 
spots” tended to decrease with an increase of tumor size 
and stage progression. On the other hand, the expres-
sion of VEGFs in SCC was significantly associated with 
ABSTRACT 
Background    Squamous cell carcinoma (SCC) of 
the oral region often metastasizes to the cervical lymph 
nodes. To investigate whether the risk of cervical lymph 
node metastasis are predictable through lymphatic ves-
sel density (LVD) and vascular endothelial growth fac-
tor (VEGF) expression, we assessed the relationship 
between LVD and clinicopathological parameters, and 
VEGF expression in SCC of the oral region. 
Methods    The subjects were 109 patients with SCC of 
the oral region including the lip. Clinicopathological pa-
rameters examined for the association with LVD in a peri-
tumoral hot spot were lymph node metastasis, histological 
grade and disease stage. The association with VEGF 
expression was similarly studied. LVD was detected by 
immunohistochemistry using D2-40. 
Results    LVD was significantly higher in lip cancer 
than in other oral tumors (P < 0.0001), while there were 
no significant differences of LVD among other cancers 
of the oral cavity. LVD tended to decrease with disease 
progression, increase of tumor size and increase of met-
astatic lymph node size. Eighty-four of 109 tumors were 
positive for VEGF-C or D. VEGF-C-positive tumor le-
sions were also positive for VEGF-D. Significantly high-
er levels of VEGF-C and D expressions were associated 
with large size of lymph node metastases (P = 0.02). 
Conclusion    SCC of the oral region including the 
lip that produces VEGF-C and D is significantly more 
likely to cause cervical lymph node metastasis. LVD in a 
peritumoral hot spot does not directly indicate the risk of 
cervical lymph node metastasis, but instead may reflect 
lymphangiogenesis due to VEGF together with loss of 
lymphatic vessels through tumor growth and progression. 
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lymphatic metastasis. This suggests that growth of lym-
phatics may be promoted by the production of VEGFs in 
tumor tissue, but this is not directly reflected by LVD in 
peritumoral hot spots. Instead, with regard to the mecha-
nism of cervical lymph node metastasis by oral SCC, 





Subjects and clinicopathological features
The subjects were 109 patients who underwent biopsy 
or surgical resection of tumors in the oral region at the 
Division of Oral and Maxillofacial Biopathological 
Surgery (Tottori University Hospital, Japan) between 
January 1991 and 2005. They did not receive radiation 
therapy nor chemotherapy before biopsy or surgical 
resection. They included 63 men and 46 women aged 
between 23 and 93 years, with a mean of 65 ± 13 years. 
Table 1 shows their clinicopathological features. Re-
garding the histology of the tumor, the final diagnosis 
was SCC based on examination of biopsy or resected 
specimens in all patients. Oral SCC was classified into 
6 types according to the location of the primary tumor: 
gingiva in 45 patients, tongue in 41 patients, buccal mu-
cosa in 8 patients, floor of the mouth in 7 patients, pal-
ate in 5 patients and lip in 3 patients (Table 2). Clinical 
tumor staging according to the TNM classification was 
as follows: stage I in 18 patients, stage II in 28 patients, 
stage III in 16 patients and stage IV in 47 patients (Table 
Table 1. Clinicopathological characteristics of 109 patients with SCC of lip and oral cavity
 Patients  LVD 
Characteristics n  (%) (mean ± SD) P-value
Gender Male 63 (57.5) 19.0 ± 11.9 0.345
 Female 46 (42.2) 21.3 ± 12.2
Age (yr)   Range                                      23–93
 Mean ± SD 65 ± 13 20.0 ± 11.9 0.928
Primary tumor size T1  20 (18.3) 23.4 ± 11.0 0.253
 T2  43 (39.4) 21.6 ± 13.9 
 T3 9 (8.3) 21.7 ± 12.3 
 T4 37 (34.0) 15.9 ± 8.9 
Size of regional lymph node metastasis N0 (no metastasis) 65 (59.6) 21.3 ± 12.6 0.608
 N1 (≤ 3 cm) 18 (16.5) 20.1 ± 13.4 
 N2 (between N1 and N3) 24 (22.0) 17.0 ± 8.6
 N3 (> 6 cm) 2 (1.8) 12.0 ± 2.8 
Clinical stage (UICC) Stage I 18 (16.5) 22.4 ± 9.7 0.971
 Stage II 28 (25.7) 22.8 ± 15.5 
 Stage III 16 (14.7) 21.9 ± 14.1 
 Stage IV 47 (43.1) 16.7 ± 8.7 
Histological differentiation Well differentiated 44 (40.4) 21.3 ± 14.1 0.708
 Moderately differentiated 46 (42.2) 19.0 ± 10.4
 Poorly differentiated 19 (17.4) 19.5 ± 10.2
LVD, lymphatic vessel density; SCC, squamous cell carcinoma; UICC, Union Internationalis Contra Cancrum.
Table 2. LVD among the primary sites of 109 patients 
with SCC
 Patient LVD 
Primary site n    (%) (mean ± SD)
Tongue 41 (37.6) 20.2 ± 8.7
Gingiva 45 (41.3) 17.8 ± 10.4
Buccal mucosa 8 (7.3) 25.9 ± 19.4
Oral floor 7 (6.4) 15.3 ± 8.1
Palate 5 (4.6) 14.6 ± 7.2
Lip 3 (2.8) 54.3 ± 6.0***
LVD, lymphatic vessel density; SCC, squamous cell carcinoma.
***P < 0.0001.
1). The subjects were also classified into 4 groups based 
on tumor size: T1 in 20 patients, T2 in 43 patients, T3 
in 9 patients and T4 in 37 patients (Table 1). Histologi-
cally, the tumor was classified as well differentiated in 
44 patients, moderately differentiated in 46 patients and 
poorly differentiated in 19 patients. With regard to the 
presence or absence of cervical lymph node metastasis, 
there was no cervical lymph node metastasis (N0) in 65 
subjects, while 18 had a solitary lymph node metastasis 
measuring 3 cm or less in maximum diameter (N1) on 
the same side as the primary tumor, 2 had a lymph node 
metastasis measuring 6 cm or more in maximum diam-
eter (N3) and 24 had a lymph node metastasis between 
N1 and N3 (N2). We performed histopathological as-
sessment of LVD using the pathological specimens from 
each group. Furthermore, to assess the factors present at 
an early stage that could lead to lymphatic metastasis, 
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we also examined the association between the above-
mentioned clinicopathological parameters and LVD in 
stage-I and II patients. The present study was performed 
with approval from the ethics committee of the Tottori 
University Faculty of Medicine (approval number: 1499).
 
Histopathological examination
Serial paraffin sections measuring 4 µm in thickness 
were prepared from tumor tissue blocks obtained at bi-
Table 3. Antibodies used and dilutions
Antibody Clone Dilution Antigen retrieval Source
D2-40 D2-40 1:100 Microwave heating DAKO (Glostrup, Denmark)
VEGF-C Polyclonal 1:400 Microwave heating R&D Systems (Mineapolis, MN)
VEGF-D 78923 1:100 Microwave heating R&D Systems (Mineapolis, MN)
VEGF, vascular endothelial growth factor.
Fig. 1. HE staining and D2-40 immunostaining of resected SCC 
specimens of the tongue.
A: Well differentiated SCC showing solid proliferation. 
B: There are D2-40-positive lymphatic vessels in the peritumoral 
stroma. The cytoplasm of some tumor cells at the margin of 
the cancer is also positive for D2-40. The circled area was de-
fined as the hot spot. Lymphatic vessels were counted in 2 hot 
spot fields and totaled. 
HE, hematoxylin and eosin; SCC, squamous cell carcinoma. 
opsy or surgery. One of each set of serial sections was 
subjected to hematoxylin-eosin (HE) staining and was 
used to evaluate histopathological findings according to 
the TMN classification of the Union Internationalis Con-




Immunohistochemical analysis was performed by the 
avidin-biotinylated peroxidase complex method. Paraf-
fin sections were deparaffinized, and then subjected 
to microwave heating for 10 min in 0.01 M sodium ci-
trate buffer (pH 6.0). Next, the sections were treated in 
methanol containing 0.3% hydrogen peroxide solution to 
inhibit endogenous peroxidase, incubated with a block-
ing reagent to prevent nonspecific reactions, and then 
incubated at 4 ˚C overnight with various primary anti-
bodies (Table 3) at various dilutions. The sections were 
subsequently washed with phosphate-buffered saline (pH 
7.4) and then incubated for 30 min with the biotinylated 
secondary antibody at room temperature, followed by 
reaction for 1 h with avidin-biotinylated peroxidase com-
plex solution at room temperature. Color was developed 
with 3-3'-diaminobenzidine-tetrahydrochloride, and 
after nuclear staining, dehydration and lucidification, 
specimens were served for microscopic examination. 
The primary antibodies used were listed in Table 3. Sec-
tions incubated in phosphate-buffered saline without any 
primary antibody were used as the negative control.
 
LVD measurement
Sections immunostained with D2-40 were used to mea-
sure the lymphatic vessel count. Clinicopathological 
findings were evaluated by 2 independent examiners (SW 
and MK) in a blinded fashion, and mean values were cal-
culated. Lymphatic vessel measurement was performed 
according to a modification of Weidner’s method (1991).12 
In brief, a region of the peritumoral stroma that was ap-
propriate for determining the lymphatic vessel count was 
defined as a hot spot (Fig. 1), and was used to measure 
the number of lymphatic vessels positive for D2-40 in 
each of 2 arbitrary fields under an objective lens with a 
magnification power of 20 (field area: 0.949 mm2). Then 
the total number of lymphatic vessels in the 2 fields was 
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hot spot was compared among groups stratified for age, 
sex, primary tumor site, clinical stage, tumor size, grade 
and the presence or absence of lymphatic metastasis.
 
Examination of VEGF-C and D expressions
Staining for VEGF-C or D was performed using serial 
paraffin sections. For both VEGF-C and VEGF-D, more 
than 50% positive tumors cells were judged as positive 
staining. We examined the relationship between the re-




Relationships between clinicopathological parameters 
and LVD were assessed by multivariate analysis using a 
multiple linear regression model. Associations between 
the expression of VEGF-C or D and clinicopathologi-
cal parameters or LVD were investigated by multivariate 
logistic regression analysis. For statistical analysis of the 
relationship between the primary site and LVD, analysis of 
variance was used, followed by multiple comparison with 
the Dunnett’s method and Scheff’s method. SPSS Statis-
tics software version 19.0 (IBM, Tokyo, Japan) was used 
for all analyses, and statistical significance was accepted at 




Site-specific LVD in oral SCC
The LVD measured in the 2 hot spot fields was 20.2 ± 8.7 
for tongue cancer, 17.8 ± 10.4 for gingival cancer, 25.9 
± 19.4 for cancer of the buccal mucosa, 15.3 ± 8.1 for 
oral floor cancer, 14.6 ± 7.2 for palatal cancer and 54.3 ± 
6.0 for lip cancer (Table 2). HE- and D2-40-stained sec-
tions of representative examples of tongue, gingiva, lip, 
palate and oral floor cancers are shown in Figs. 2A to J. 
In the peritumoral stromal tissue, D2-40-poisitive lym-
phatic vessels of various sizes were observed (Figs. 2B, 
D, F, H and J). Blood vessel components apart from the 
lymphatic endothelium and the negative controls were 
negative for D2-40 staining. In addition, the margins 
of the tumor tissue and in infiltrating areas were D2-40 
positive (Figs. 2B and F). Site-specific LVD showed a 
significant difference between lip cancer and cancers of 
the gingiva, tongue, buccal mucosa, oral floor and palate 
(post-hoc test, P < 0.0001). The LVD of lip cancer was 
significantly higher than that for cancers of the tongue, 
gingiva, buccal mucosa, oral floor and palate. However, 
no significant differences of LVD were noted among 
cancers of the tongue, gingiva, buccal mucosa, oral floor 
and palate.
 
Association between clinicopathological findings 
and LVD
In relation to tumor size, LVD was 23.4 ± 11.0 for T1, 
21.6 ± 13.9 for T2, 21.7 ± 12.3 for T3 and 15.9 ± 8.9 for 
T4 disease (Table 1). Regarding the association between 
LVD and tumor size, the lymphatic vessel count tended 
to decrease with an increase of tumor size, but there 
was no significant difference of LVD among each tumor 
size category. LVD was 21.3 ± 12.6 in patients without 
lymph node metastasis (N0 group), 20.1 ± 13.4 in the N1 
group, 17.0 ± 8.6 in the N2 group and 12.0 ± 2.8 in the 
N3 group. There were no significant differences of LVD 
among these 4 groups, although LVD tended to decrease 
with an increase of lymph node metastasis size. Accord-
ing to the clinical tumor stage, LVD was 22.4 ± 9.7 in 
stage I, 22.8 ± 15.5 in stage II, 21.9 ± 14.1 in stage III 
and 16.7 ± 8.7 in stage IV. The lymphatic vessel count 
tended to decrease with stage progression, but multiple 
regression analysis revealed no significant difference 
of LVD between each stage. Regarding the histological 
grade of SCC, LVD was 21.3 ± 14.1 in well-differenti-
ated SCC, 19.0 ± 10.4 in moderately differentiated SCC 
and 19.5 ± 10.2 in poorly differentiated SCC. There was 
no significant difference of LVD among the different 
grades of SCC. No significant differences of LVD were 
found in relation to sex and age.
 Assessment of the association between LVD and 
clinicopathological findings in stage-I and II patients re-
vealed no significant correlations between LVD and age 
(P = 0.712), sex (P = 0.873), tumor size (P = 0.772) or 
tumor histological grade (P = 0.057) by multiple regres-
sion analysis.
Relationship between VEGF-C or D immunostain-
ing and LVD or clinicopathological findings
Immunostaining was positive for VEGF-C and D in the 
cytoplasm of tumor cells (Figs. 3B, E and F). Tumor 
tissue with more than 50% positive cells is judged to 
be positive for VEGF staining. Based on this criterion, 
we determined 84 of the 109 tumors to be positive for 
VEGF-C (Fig. 3B and E) and 25 of them, negative (Fig. 
3G). In the case of VEGF-D, we determined 84 of the 
109 tumors to be positive for VEGF-D, which were also 
positive for VEGF-C (Figs. 3E and F). In other words, 
the expression patterns of VEGF-C and D were identi-
cal. 
 When we investigated the relationship between LVD 
and staining for VEGF-C or D, LVD was 19.7 ± 11.9 in 
VEGF-C-positive patients and 21.2 ± 12.2 in VEGF-
C-negative patients. Regarding the association between 
LVD and either positive or negative staining for VEGF-
C or D, logistic regression analysis revealed no statisti-
cally significant associations. When VEGF-C/VEGF-
33
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Fig. 2. HE staining and D2-40 
immunostaining of SCC tissues in 
representative patients.
 
ACEGI: Well differentiated SCC 
showing cord-like proliferation 
and invasion. Bar = 100 µm. 
 
BDFHJ: There are D2-40-positive 
lymphatics in the peritumoral 
stroma. These lymphatic vessels 
are clearly distinguishable from 
D2-40-negative blood vessels.
  
HE, hematoxylin and eosin; SCC, 
squamous cell carcinoma.       
ACEGI:  HE staining  BDFHJ:  D2-40 immunostaining 
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Fig. 3. HE staining, D2-40 immunostaining, VEGF-C  immunostaining and VEGF-D immunostaining of SCC.
A: Well-differentiated SCC showing cord-like proliferation and invasion.
B: The cytoplasm of tumor cells is positive for VEGF-C staining. Non-neoplastic squamous cells in the tongue mucosa are negative for 
VEGF-C. 
C: Small cords of SCC cells proliferated and invaded the stromal tissues of the tongue.
D: Several D2-40-postivie lymphatics are observed in the stroma in the vicinity of the tumor tissues. Blood vessels are negative for D2-
40.
E: The majority of the tumor cell nests are strongly positive for VEGF-C. 
F: The majority of tumor cell nests are positive for VEGF-D. The VEGF-D staining pattern corresponds to that of VEGF-C.
G: A few tumor cells are positive for VEGF-C, but many tumor cells are negative. 
H: Many D2-40-positive lymphatic vessels can be seen in the stroma near the tumor tissues. Tumor cells in the infiltrating lesion (left 
upper region) are also strongly positive for D2-40. 
The same magnification was used for A to H. Bar = 100 µm. HE, hematoxylin and eosin; SCC, squamous cell carcinoma; VEGF, vascu-
lar endothelial growth factor.     
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D positivity and D2-40 staining were compared, LVD 
was low in some VEGF-C- and D-positive tumors (Figs. 
3D–F), while LVD was high in some VEGF-C- and D-
negative tumors (Figs. 3G and H).
 Regarding the relationship between clinicopatholog-
ical findings and VEGF staining, the VEGF-C-positive 
rate increased significantly with an increase in the size 
of lymph node metastases (logistic regression analysis, P 
= 0.02). Similarly, the VEGF-D-positive rate increased 
significantly with an increase in the size of lymph node 
metastases (P = 0.02). However, no significant associa-
tion was observed between VEGF expression and the 





SCC of the oral region is likely to cause lymph node me-
tastases, which influences the prognosis. For this reason, 
several studies have investigated the association between 
lymphatic vessels and clinicopathological findings in 
patients with oral SCC.9,13,14 However, these studies 
mainly focused on SCC of the tongue and the number 
of patients investigated was limited. In the present study, 
we investigated the relationship between histopathologi-
cally assessed LVD and clinicopathological findings in 
109 patients with SCC of various parts of the oral cavity, 
including the lip; i.e., the gingiva, tongue, buccal mu-
cosa, floor of the mouth and palate. No study has ever 
examined more than 100 patients with SCC originating 
in the oral region, particularly with stratification accord-
ing to the site of the primary tumor.
 With regard to LVD in oral SCC, the tumor site-
specific LVD was 28.3 ± 12.5 for tongue cancer and 16.5 
± 5.66 for cancer at other sites.13 The peritumoral LVD 
of oral cancer ranged widely from 1 to 43.9  Moreover, 
the LVD of oral SCC was 12.89 ± 9.31.14 In the pres-
ent study, we totalled the lymphatics in two 0.949-mm2 
fields. When converted to a per-unit value, our LVD val-
ues were slightly lower than or similar to those reported 
above.
 As we observed in the present investigation of site-
specific LVD, lip cancer showed a significantly higher 
LVD level than cancer arising at other sites.15, 16 Studies 
on lip cancer were not many, especially with regard to 
LVD, and no study reported higher LVD in the peritu-
moral “hot spot” of lip cancer than in other types of oral 
cancer. This result may be related to an anatomical fea-
ture of the lip, high vascularity, which imparts the char-
acteristic red color. Despite the high LVD observed in 
lip cancer at the hot spot, the prognosis of this cancer is 
quite good, with a low frequency of cervical lymph node 
metastasis. Other factor like the distance from the cervi-
cal lymph nodes might also influence the biological be-
havior of lip cancer. Furthermore, the lip is a prominent 
site where tumors are easily detected, which contributes 
to early diagnosis and treatment. This might also ex-
plain why the prognosis of lip cancer is better than that 
of cancer of other oral regions. In general, oral cancer 
of the tongue and floor of the mouth metastasize to the 
cervical lymph nodes relatively often. However, in the 
present investigation of site-specific LVD in peritumoral 
hot spots, we found no significant differences among 
sites other than the lip, such as the gingiva, tongue, buc-
cal mucosa, oral floor and palate. Therefore, based on 
the mechanism of cervical lymph node metastasis which 
occurs more easily in cancer of the tongue and oral floor 
than in cancer of the gingiva and palate,  we found that 
the LVD of hot spots does not directly reflect suscepti-
bility to cervical lymph node metastasis.  
 Regarding the relationship between LVD and oral 
SCC, lymphangiogenesis was associated with metasta-
sis-free survival in tongue cancer patients.13 In addition, 
the presence of lymph node metastasis was significantly 
associated with a higher intratumoral lymphatic density, 
a higher incidence of tumor relapse and shorter levels of 
5-year overall survival and disease-free survival.9 More-
over, LVD was correlated with tumor grade and nodal 
status in oral SCC patients.17 In the present study of 109 
patients with lip and oral SCC, we assessed all correla-
tions between LVD and clinicopathological parameters 
including tumor size, presence or absence of lymph node 
metastases, histological grade and clinical tumor stage; 
however, multivariate analysis revealed no significant as-
sociations between LVD and clinicopathological param-
eters. In addition, we examined the associations between 
LVD and these clinicopathological parameters among 
stage-I and II patients without lymph node metastasis, 
and found no significant associations between LVD and 
any of these factors. Rather, our results showed lymphat-
ic vessel count decrease along with tumor size increase, 
which tended to decrease with the advance of disease 
stage or lymph node metastasis. In an investigation of 
adenocarcinoma of the rectum examined on the associa-
tion between LVD and clinicopathological factors,18 the 
prognosis was not necessarily correlated with the LVD 
at the peripheral zone of the tumor or inside tumor tis-
sue, but actually with lymphangiogenesis in the regional 
lymph nodes. In patients with oral cancer, the primary 
tumor induces sentinel lymph node lymphagiogenesis 
prior to the onset of lymph node metastasis.19 In other 
words, lymphagiogenesis in the regional lymph nodes, 
rather than peritumoral lymphatic hyperplasia, is an im-
portant prognostic factor.
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 VEGF-C and D promote lymphatic vessel growth 
and are involved in lymphangiogenesis.20 Both VEGFs 
are related to LVD, and bind to VEGF receptor-3 (VEG-
FR-3) on the surface of lymphatic endothelial cells to 
induce the proliferation and growth of new lymphatic 
vessels.21 Expression of both VEGFs has been reported 
in oral cancer.22 In the present study, immunostaining of 
oral SCC specimens showed a high positivity for VEGF-
C and D (84/109 both; 77%). Moreover, when the stain-
ing patterns were compared, VEGF-C and D showed 
almost identical patterns. Significant associations be-
tween VEGF-C expression and LVD were reported.14,17 
We observed no significant association of VEGF-C and 
D positivity with LVD, but significantly more VEGF-
C and D positivity among patients with larger lymph 
node metastases. It is likely that lymphangiogenesis oc-
curs due to the production of VEGF-C by tumor cells, 
but conversely LVD in peritumoral hot spots tends to 
decrease with an increase of tumor size and stage pro-
gression. The production of VEGF-C by tumor cells 
also promotes lymphangiogenesis, but lymphatic ves-
sels at the tumor periphery are damaged due to tumor 
progression and this may lead to a decrease of the LVD. 
Furthermore, there is a possibility that lymphangiogen-
esis also occurs in remote sentinel lymph nodes due to 
VEGF production. In relation to VEGF-C and D expres-
sions in tumor tissue, it is thought that lymphagiogenesis 
in the regional lymph node  affects the prognosis. These 
reports support our present finding that lymph node me-
tastasis was more frequent in VEGF-C and D-positive 
patients.
 In conclusion, we examined the association between 
clinicopathological parameters and LVD or the expres-
sion of VEGF-C or D in SCC of the oral region includ-
ing the lip. Our site-specific investigation revealed a 
significant increase of the LVD in lip cancer, whereas 
no significant difference of LVD was observed in can-
cers arising at other sites. In addition, in terms of the 
relationship between clinicopathological parameters and 
LVD, LVD tended to decrease with increasing disease 
stage and size of lymph node metastasis. Furthermore, 
patients with larger lymph node metastases were sig-
nificantly more likely to be positive for VEGF-C and 
D. Peritumoral LVD decreased with tumor progression, 
while the expression of VEGF showed a strong correla-
tion with lymph node metastasis, suggesting that further 
study is needed to determine the mechanisms of cervical 
lymph node metastasis in patients with oral SCC.
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